AI coding returns commoditize faster than FDA timelines extend
Mercyhealth's revenue cycle gains vanish when competitors deploy identical vendor tools while regulatory erosion accelerates approvals, not delays
drop in FDA device review times during 2019-2020 staff turnover
FDA's 2019-2020 response to device backlog under political pressure was expedited pathways and reduced clinical evidence requirements, cutting median 510(k) times 15% even as staff turnover spiked
One pattern. Trace it.
- 01
A pattern worth naming
(2) FDA capacity metrics — track whether Congress schedules hearings on FDA staffing post-DOGE; the Senate HELP Committee calendar is the key indicator. Any formal FDA acknowledgment of extended review timelines is a red flag for device and drug pipeline planning.
- Shift
Revenue cycle AI vendors already serve 60%+ of U.S. hospitals, erasing first-mover advantage within 18 months
- Shift
FDA now faces identical political pressure that previously accelerated approvals through lowered evidentiary bars
- Shift
Rare-disease M&A valuations peak as Angelini pays $4.1B for assets facing biosimilar and compounding threats
“If FDA review timelines stretch another six months, which three pipeline products in our formulary plan become procurement risks we can't absorb?”
Ask your CFO whether AI coding ROI models assume competitive advantage or commodity returns when every peer deploys by year-end
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →